Bionic Eye Beats Blindness in Major NEJM Trial

The Disease That Steals Sight

Geographic atrophy (GA) — the most severe form of age-related macular degeneration (AMD) — is the leading cause of irreversible blindness in the elderly, affecting more than 5 million people worldwide. It silently destroys the macula, the central zone of the retina responsible for sharp vision, leaving patients unable to read, drive, or recognize faces. Until now, medicine had no way to restore what GA takes away. A landmark study published this week has changed that.

How the PRIMA Implant Works

The PRIMA system, developed by Silicon Valley startup Science Corporation, is a wireless subretinal prosthesis measuring just 2×2 mm. It contains 378 photovoltaic pixels — miniature solar cells implanted beneath the retina in the precise zone where photoreceptors have been destroyed. A camera embedded in specialized glasses captures the surrounding scene and transmits near-infrared light pulses to the implant, which converts them into electrical signals that stimulate surviving retinal neurons downstream.

The glasses also allow users to adjust zoom — up to 12x magnification — and contrast, giving patients meaningful control over their artificial sight. The entire system operates without wires or external power sources penetrating the eye, a key advantage over earlier retinal prostheses.

Landmark Trial Results

The PRIMAvera trial, conducted at 17 medical centers across France, Germany, Italy, the Netherlands, and the United Kingdom, enrolled 38 patients aged 60 and older. Among the 32 who completed the 12-month follow-up, results were striking:

• 81% experienced clinically meaningful visual acuity improvement
• 84% could read letters, words, or numbers at home using the device
• Average gain: approximately 25 letters on the standard eye chart — roughly five full lines
• The most dramatic case: one patient improved by 59 letters, equivalent to 12 lines of vision

"It's the first time that any attempt at vision restoration has achieved such results in a large number of patients," said lead author Dr. José-Alain Sahel of the UPMC Vision Institute. "More than 80% of the patients were able to read letters and words, and some of them are reading pages in a book."

The results were published in the New England Journal of Medicine, one of medicine's most prestigious peer-reviewed journals, which in an accompanying editorial called the PRIMA implant "the first treatment to restore vision" in geographic atrophy patients.

Safety Profile

The trial recorded 26 serious adverse events among 19 participants — including elevated intraocular pressure, retinal tears, and hemorrhaging — most linked to the surgical procedure rather than the device itself. Crucially, 95% of complications resolved within two months, and all procedure-related side effects had cleared by the 12-month mark. No long-term device-related safety concerns were identified.

What Comes Next

Science Corporation has submitted regulatory applications in both Europe and the United States. If approved, PRIMA would become the first therapy capable of restoring functional central vision to GA patients — a population for which no curative treatment currently exists.

The stakes extend well beyond individual patients. With populations aging rapidly across the developed world, AMD prevalence is projected to climb sharply over the coming decades. Researchers, including Stanford's Dr. Daniel Palanker, are already exploring ways to push outcomes above the legal blindness threshold — a goal that, until this trial, seemed out of reach.